Saturday 17 October 2026
Export XCUR’s income statement to Excel — free account
Exicure, Inc.
XCUR Healthcare Biotechnology
Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022. In the quarter to June 2026, EPS grew 56.1% and free cash flow grew 65.4%, each against the same quarter a year earlier.
1.11
0.01
−0.89%
Follow XCUR
Exicure, Inc. (XCUR) P/E ratio
Exicure, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.1× (June 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.2× | 0.00% |
| FY2016 | 0.2× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.1×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | n/m |
| XCUR Exicure, Inc. | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)